about
Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas.Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence.Bacterial cytoplasm as an effective cell compartment for producing functional VHH-based affinity reagents and Camelidae IgG-like recombinant antibodiesTrop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma.Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissuesDiagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patientsTrop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody.Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer managementEvaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug deliveryLandscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis.Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues.Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response.HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm.Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients.Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcomeDifferential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapyCorrelation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patientsCancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosisPrenatal presentation and postnatal evolution of a patient with Jansen metaphyseal dysplasia with a novel missense mutation in PTH1RHuman papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L
P50
Q33442189-149F079F-DFB8-4F48-B282-95F17CAF8958Q33487445-BFFA2C44-ECE6-4337-B171-4611C70FD2A8Q34234412-9A24D4A7-3325-42E4-B130-33729F81BA61Q34476583-A3A2E950-BA12-44FA-8AAC-D34BD38903C6Q34633600-53CD4B58-F860-43D7-BCE7-B17476582BF7Q35006871-93BC61D7-8678-475E-B3DF-E705447094DFQ35600838-073B8048-C6AE-410F-A692-E5B4CE3084E1Q35612779-96812833-578C-48B3-91EF-29E237B482EDQ36544167-98AC3387-928B-4890-A5D9-B7A45D1C4B62Q36637663-D959507E-6D9A-4C0B-AB90-78DFCA484AFCQ36996794-60A9791F-0333-4B6E-B386-A4B24D3C31DFQ37466755-0114AAF3-138D-4453-B49C-F1AFE889CD3CQ39167159-280BF007-0B8B-4B3D-8791-768235AFB7C6Q43263678-71FFAA74-E375-4331-8172-6189A66BC423Q43438121-2EC81DD6-40F9-4989-A298-E612A55A9444Q51570551-4BCAD80C-698E-454F-B8B8-1D791E7F4C49Q53349518-D3C7E1C5-551A-4446-92D3-3C1BACDBDB55Q56836325-989D7AAB-427B-40C5-8AAD-3F841B3AD1F9Q56836339-82055721-397C-4B9F-A572-75D13D919730Q56836341-4D7C2129-582E-42FE-8BBE-B730EFF8C2C7Q58487862-85D51CAA-E1C9-4384-B020-C3C1BA5C9AE7Q60655481-2EF8AAEC-CB3D-41C2-8230-DE144638BDEFQ60655522-D78735D9-F57A-4289-831F-CAB72F011812
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Chiara Romani
@ast
Chiara Romani
@en
Chiara Romani
@es
Chiara Romani
@nl
Chiara Romani
@sl
type
label
Chiara Romani
@ast
Chiara Romani
@en
Chiara Romani
@es
Chiara Romani
@nl
Chiara Romani
@sl
prefLabel
Chiara Romani
@ast
Chiara Romani
@en
Chiara Romani
@es
Chiara Romani
@nl
Chiara Romani
@sl
P106
P1153
12244603900
P21
P31
P496
0000-0001-7916-2704